The shares of BeiGene, Ltd. have increased by more than 59.54% this year alone. The shares recently went up by 3.99% or $5.98 and now trades at $155.90. The shares of Genocea Biosciences, Inc. (NASDAQ:GNCA), has slumped by -12.07% year to date as of 02/22/2018. The shares currently trade at $1.02 and have been able to report a change of 4.08% over the past one week.
The stock of BeiGene, Ltd. and Genocea Biosciences, Inc. were two of the most active stocks on Thursday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.
Profitability and Returns
Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. BGNE has an EBITDA margin of 2.72%, this implies that the underlying business of BGNE is more profitable. The ROI of BGNE is -31.60% while that of GNCA is -77.30%. These figures suggest that BGNE ventures generate a higher ROI than that of GNCA.
Liquidity and Financial Risk
The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for BGNE is 9.30 and that of GNCA is 1.60. This implies that it is easier for BGNE to cover its immediate obligations over the next 12 months than GNCA. The debt ratio of BGNE is 0.21 compared to 4.24 for GNCA. GNCA can be able to settle its long-term debts and thus is a lower financial risk than BGNE.
BGNE currently trades at a P/B of 8.75, and a P/S of 37.39 while GNCA trades at a P/B of 7.85, This means that looking at the earnings, book values and sales basis, BGNE is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.
Analyst Price Targets and Opinions
The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of BGNE is currently at a 41.21% to its one-year price target of 110.40. Looking at its rival pricing, GNCA is at a -88% relative to its price target of 8.50. This figure implies that over the next one year, GNCA is a better investment.
When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), BGNE is given a 1.90 while 2.00 placed for GNCA. This means that analysts are more bullish on the outlook for GNCA stocks.
Insider Activity and Investor Sentiment
Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for BGNE is 6.13 while that of GNCA is just 3.07. This means that analysts are more bullish on the forecast for GNCA stock.
The stock of Genocea Biosciences, Inc. defeats that of BeiGene, Ltd. when the two are compared, with GNCA taking 5 out of the total factors that were been considered. GNCA happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, GNCA is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for GNCA is better on when it is viewed on short interest.